CBIO SCHEDULE 13G/A: SEC filing
Vestal Point Capital, LP
Filed with the SEC on · accession 0000902664-26-004580
CBIO filed a SCHEDULE 13G/A (schedule 13g/a) with the SEC on Nov 16, 2026. Vestal Point Capital, LP filed an amended Schedule 13G reporting beneficial ownership of 3,000,000 ordinary shares, or 8.1%, of Crescent Biopharma, Inc. as of September 30, 2026.
Summary of the filing
Vestal Point Capital, LP filed an amended Schedule 13G reporting beneficial ownership of 3,000,000 ordinary shares, or 8.1%, of Crescent Biopharma, Inc. as of September 30, 2026. The filing is a passive investment disclosure under Rule 13d-1(b).
Key details
✦ Ask GOAX AI about this filing — what it means for CBIO, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for CBIO?
Click hereFrequently asked questions
What did CBIO file with the SEC on Nov 16, 2026?
CBIO filed a SCHEDULE 13G/A (SEC filing). Vestal Point Capital, LP filed an amended Schedule 13G reporting beneficial ownership of 3,000,000 ordinary shares, or 8.1%, of Crescent Biopharma, Inc. as of September 30, 2026. The filing is a passive investment disclosure under Rule 13d-1(b).
How do I read a SCHEDULE 13G/A?
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G/A (schedule 13g/a): A report the company filed with the SEC (the US market regulator).
Other CBIO SEC filings
Get alerts when CBIO files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days